Sammanfattning

Overexpression of the receptor tyrosine kinase MET has been linked to poor survival in several cancer types, and MET has been suggested to interact with stem cell networks. In vitro studies have further suggested a possible benefit of a combined treatment using PARP and MET inhibitors. We used a tissue microarray (TMA) with 130 samples of advanced-stage high-grade serous fallopian tube/ovarian cancer (HGSC) to investigate the prognostic value of MET protein expression alone and in combination with the stem cell factor SOX2. The possible synergistic effects of a PARP and MET inhibitor treatment were evaluated in two cell lines with BRCA1 or BRCA2 deficiency and in their BRCA1/2-proficient counterparts. Patients with tumors positive for MET had worse overall survival (log-rank test, p = 0.015) compared to patients with MET-negative tumors. The prognostic role of MET was even more prominent in the subgroup of patients with SOX2-negative tumors (p = 0.0081). No synergistic effects of the combined treatment with PARP and MET inhibitors were found in the cell lines examined. We conclude that MET expression could be used as a marker for OS in HGSC and that stemness should be taken into consideration when evaluating the mechanisms of this effect.
Originalspråkengelska
Artikelnummer742
TidskriftGenes
Volym12
Nummer5
DOI
StatusPublished - 2021 maj 14

Ämnesklassifikation (UKÄ)

  • Medicinsk genetik
  • Cancer och onkologi

Fingeravtryck

Utforska forskningsämnen för ”MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här